Noninvasive assessment of pediatric brain tumors

Cancer Biology and Therapy

Volumn 8, Issue 20, 2009, Pages 1881-1888

  Warren, Katherine E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Diffusion; Glioma; Imaging; Pediatric; Perfusion; Spectroscopy; Tumor measurement

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM;

BRAIN TUMOR; CANCER DIAGNOSIS; CANCER THERAPY; CHILDHOOD CANCER; GLIOMA; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SPECTROSCOPY; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; CHILD; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 73549095271     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.20.9805     Document Type: Review

References (81)

1. Legler J, Gloeckler Ries L, Smith M, Warren J, Heineman E, Kaplan R, et al. Brain and other Central Nervous System Cancers: Recent Trends in Incidence and Mortality. J Natl Cancer Inst 1999; 91:1382-90.
2. Louis D, Holland E, Cairncross J. Glioma classification: a molecular reappraisal. Am J Pathol 2001; 159:779-86.
3. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
4. Macdonald D, Cascino T, Schold S Jr, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-80.
5. Hayward R, Patronas N, Baker E, Vezina G, Albert P, Warren K. Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol 2008; 90:57-61.
6. Price S, Jena R, Burnet N, Hutchinson P, Dean A, Pena A, et al. Improved delineation of glioma margins and regions of infiltration with use of diffusion tensor imaging: an image-guided biopsy study. AJNR 2006; 27:1969-74.
7. Kumar A, Leeds N, Fuller G, Van Tassel P, Maor M, Sawaya R, et al. Malignant gliomas: MRI spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217:377-84.
8. Weybright P, Sundgren P, Maly P, Hassan D, Nan B, Rohrer S, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005; 185:1471-6.
9. Gururangan S, Cavazos C, Ashley D, Herndon J, 2nd, Bruggers C, Moghrabi A, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 2002; 20:2951-8.
10. Packer R, Ater J, Allen J, Phillips P, Geyer R, Nicholson H, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86:47-54.
11. Petrick N, Brown D, Suleiman O, Meyers K. Imaging as a Tumor Biomarker in Oncology Drug Trials for Lung Cancer: The FDA Perspective. Clin Pharmacol Ther 2008; 84:523-5.
12. Law M, Young R, Babb J, Peccerelli N, Chheang S, Gruber M, et al. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247:490-8.
13. Smith E, Carlos R, Junck L, Tsien C, Elias A, Sundgren P. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009; 192:45-52.
14. Soares D, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009; 64:12-21.
15. 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995; 5:157-63.
16. Shimizu H, Kumabe T, Tominaga T, Kayama T, Hara K, Ono Y, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Amer J Neurorad 1996; 17:737-47.
17. Burtscher I, Holtas S. Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001; 13:560-7.
18. Nelson S. Magnetic resonance spectroscopic imaging. IEEE Engineering in Medicine and Biology Magazine 2004; 30-9.
19. Fulham M, Bizzi A, Dietz M, Shih H, Raman R, Sobering G, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185:676-86.
20. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn J, Alger J, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopic imaging study. J Neurosurg 1997; 87:516-24.
21. Castillo M, Kwock L. Proton MR spectroscopy of common brain tumors. Neuroimag Clin N Am 1998; 8:733-52.
22. 1H nuclear magnetic resonance spectroscopy index for non-invasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat Res 1998; 150:38-42.
23. Warren K, Frank J, Black J, Hill R, Duyn J, Aikin A, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18:1020-6.
24. Burtscher I, Skagerberg G, Geijer B, Englund E, Stahlberg F, Holtas S. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000; 21:84-93.
25. Gupta R, Cloughesy T, Sinha U, Garakian J, Lazareff J, Rubino G, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000; 50:215-26.
26. Tzika A, Astrakas L, Zarifi M, Zurakowski D, Pouissaint TY, Goumnerova L, et al. Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer 2004; 100:1246-56.
27. Marcus K, Astrakas L, Zurakowski D, Zarifi M, Mintzopoulos D, Young T, et al. Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers. Int J Oncol 2007; 30:651-7.
28. Pirzkall A, Li X, Oh J, Chang S, Berger M, Larson D, et al. 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004; 59:126-37.
29. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32:1323-9.
30. Haage R, Wong T, Coleman R. Positron emission tomography: brain tumors and lung cancer. Radiol Clin North Am 2001; 39:871-81.
31. Patronas N, Di Chiro G, Kufta C, Bairamian D, Kornblith P, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62:816-22.
32. 18F-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-80.
33. Eary J, Mankoff D, Spence A, Berger M, Olshen A, Link J, et al. 2-[C-11] thymidine imaging of malignant brain tumors. Cancer Res 1999; 59:615-21.
34. Shields A, Mankoff D, Link J, Graham M, Eary J, Kozawa S, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-62.
35. Shields A, Grierson J, Dohmen B, Machulla H, Stayanoff J, Lawhorn-Crews J, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-6.
36. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Imag 2004; 31:1659-72.
37. Sherley K, Kelly T. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 1263:8350-8.
38. 18F-FLT and Thymidine Analogs: Promise and Pitfalls. J Nucl Med 2003; 44:1432-4.
39. Munch-Petersen B, Cloos L, Jensen H, Trysted G. Human thymidine kinase 1. Regulation of normal and malignant cells. Adv Enzyme Regul 1995; 35:69-89.
40. Yamamoto Y, Wong T, Turkington T, Hawk T, Reardon D, Coleman R. 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 2006; 8:340-7.
41. 18F] 3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Imag 2005; 32:653-9.
42. Sloan A, Shields A, Kupsky W, Heilbrun N, Abrams J, Barger G, et al. Superiority of [F-18] FLT PET compared to FDG PET in assessing proliferative activity and tumor physiology in primary and recurrent intracranial gliomas. Neuro-Oncology 2001; 3:345.
43. 18F-Fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46:1948-58.
44. 18F] Fluorothymidine positrom emission tomography: a pilot study. J Clin Oncol 2007; 25:4714-21.
45. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32:2534-9.
46. Cianfoni A, Colosimo C, Basile M, Wintermark M, Bonomo L. Brain perfusion CT: principles, technique and clinical applications. Radiol Med 2007; 112:1225-43.
47. Young Poussaint T, Rodriguez D. Advanced neuroimaging of pediatric brain tumors: MR diffusion, MR perfusion and MR spectroscopy. Neuroimag Clin N Am 2006; 16:169-92.
48. Petrella J, Provenzale J. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol 2000; 175:207-19.
49. Kassner A, Roberts T. Beyond perfusion: cerebral vascular reactivity and assessment of microvascular permeability. Top Magn Reson Imaging 2004; 15:58-65.
50. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171:1479-86.
51. Roberts H, Roberts T, Brasch R, Dillon W. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21:891-9.
52. Mills S, Patankar T, Haroon H, Baleriaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006; 27:853-8.
53. Bernsen H, van der Kogel A. Antiangiogenic therapy in brain tumor models. J Neurooncol 1999; 45:247-55.
54. Barrett T, Kobayashi H, Brechbiel M, Choyke P. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 2006; 60:353-66.
55. Vezina L. Imaging of Central Nervous System tumors in children: advances and limitations. J Child Neurol 2008; 23:1128-35.
56. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006; 27:475-87.
57. Law M, Yang S, Wang H, Babb J, Johnson G, Ch S, et al. Glioma grading: sensitivity, specificity and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24:1989-98.
58. Cha S, Knopp E, Johnson G, Wetzel S, Litt A, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223:11-29.
59. Knopp E, Cha S, Johnson G, Mazumdar A, Golfinos J, Zagzag D, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211:791-8.
60. Aronen H, Gazit I, Louis D, Buchbinder B, Pardo F, Weisskoff R, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191:41-51.
61. Ball W Jr, Holland S. Perfusion imaging in the pediatric patient. Magn Reson Imaging Clin N Am 2001; 9:207-30.
62. Shin J, Lee H, Kwun B, Kim J, Kang W, Choi C, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002; 179:783-9.
63. Hakyemez B, Erdogan C, Ercan I, Ergin N, Uysal S, Atahan S. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005; 60:493-502.
64. Tzika A, Vajapeyam S, Barnes P. Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997; 18:203-18.
65. Tzika A, Cheng L, Goumnerova L, Madsen J, Zurakowski D, Astrakas L, et al. Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J Neurosurg 2002; 96:1023-31.
66. Poptani H, Puumalainen A, Grohn O, Loimas S, Kainulainen R, Yia-Herttuala S, et al. Monitoring thymidine kinase and gancyclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998; 5:101-9.
67. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier S, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001; 61:4971-3.
68. Chenevert T, Stegman L, Taylor J, Robertson P, Greenberg H, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92:2029-36.
69. Moffat B, Chenevert T, Lawrence T, Meyer C, Johnson T, Dong Q, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102:5524-9.
70. Smith J, Cha S, Mayo M, McDermott M, Parsa A, Chang S, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma; distinguishing tumor recurrence from post-resection injury. J Neurosurg 2005; 103:428-38.
71. Mechtler L. Neuro-imaging in Neuro-Oncology. Neurol Clin 2008; 27:171-201.
72. Bukte Y, Paksoy Y, Genc E, Uca A. Role of diffusion-weighted MR in differential diagnosis of intracranial cystic lesions. Clin Radiol 2005; 60:375-83.
73. Gauvain K, McKinstry R, Mukherjee P, Perry A, Neil J, Kaufman B, et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 2001; 177:449-54.
74. Kono K, Inoue Y, Nakayama K, Morino M, Ohata K, Wakasa K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001; 22:1081-8.
75. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, et al. Apparent diffusion coefficient of human brain tumors of MR imaging. Radiology 2005; 235:985-91.
76. Asao C, Korogi Y, Kitajima M, Hirai T, Baba Y, Makino K, et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005; 26:1455-60.
77. Provenzale J, McGraw P, Mhatre P, Guo A, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imagng and diffusion-tensor MR imaging. Radiology 2004; 232:451-60.
78. Jellison B, Field A, Meadow J, Lazar M, Salamat M, Alexander A. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy and tumor imaging patterns. AJNR Am J Neuroradiol 2004; 25:356-69.
79. Yu C, Li K, Xuan Y, Ji X, Qin W. Diffusion tensor tractography in patients with cerebral tumors: a helpful technique for neurosurgical planning and postoperative assessment. Eur J Radiol 2005; 56:197-204.
80. Price S, Pena A, Burnet N, Pickard J, Gillard J. Detecting glioma invasion of the corpus callosum using diffusion tensor imaging. Br J Neurosurg 2004; 18:391-5.
81. Frank J, Zywicke H, Jordan E, Mitchell J, Lewis B, Miller B, et al. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002; 9:484-8.